Novartis NVS announced positive top-line results from a late-stage study on Fabhalta (iptacopan) in adult patients with ...

Novartis (NYSE:NVS) reported positive Phase 3b data from a study of its drug Fabhalta for the treatment of the rare blood ...

Novartis has reported positive topline outcomes from the multicentre Phase IIIB APPULSE-PNH trial of oral Fabhalta (iptacopan ...

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...

Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan ...

The single-arm, open-label APPULSE-PNH trial included 52 PNH patients who were on a stable regimen with either eculizumab or ravulizumab.

Novartis’ Fabhalta improved hemoglobin levels in patients with a rare blood disorder who switched from anti-C5 therapies, ...

Novartis today announced positive top-line results from APPULSE-PNH, a Phase IIIb study on the efficacy and safety of ...

New phase IIIB data shows Novartis Fabhalta improved haemoglobin levels in adult patients with PNH who switched from anti-C5 therapy: Basel Saturday, December 7, 2024, 10:00 Hrs [ ...

Just days after getting FDA approval for Fabhalta as the first oral therapy for paroxysmal nocturnal haemoglobinuria (PNH), Novartis has reported new data showing it is also effective in C3 ...

Fabhalta (iptacopan) is a prescription drug that’s used to treat a rare type of kidney disease and a rare blood disorder. Fabhalta comes as an oral capsule that’s typically taken twice per day.

Novartis (NVS) announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral ...